KalVista Pharmaceuticals announced that the International Guideline on the Diagnosis and Management of Pediatric Patients With Hereditary Angioedema, published in the journal Allergy on February 18, 2026, recommends EKTERLY (sebetralstat) as a first‑line therapy for adolescents 12 and older.
The guideline is the first to endorse an oral on‑demand treatment for this age group, marking a significant shift from the injectable therapies that have dominated the HAE market for decades.
EKTERLY was launched in the United States on July 7, 2025, and received regulatory approvals in Germany, the United Kingdom, the European Union, Switzerland, Australia, Singapore, and Japan during 2025, positioning the drug for global commercial rollout.
Financially, KalVista reported $35 million in net product revenue for Q4 2025 and $49 million for the full year 2025, and the company projects 2026 revenue of approximately $170.8 million as adoption accelerates under the new guideline endorsement.
KalVista is preparing to submit a pediatric New Drug Application for patients aged 2 to 11 in the third quarter of 2026, expanding the drug’s potential market to younger children.
Chief Medical Officer Paul Audhya said, "We are encouraged to see this international guideline reflect the progress the HAE community has made toward more patient‑centered care, particularly for adolescents." He added, "The first‑line recommendation for EKTERLY so soon after becoming commercially available underscores the strength of our clinical data and reinforces the importance of ensuring patients have immediate access to effective on‑demand therapy." Audhya also noted, "As the first and only oral on‑demand treatment for HAE, EKTERLY uniquely enables guideline‑aligned care by supporting early intervention and simplifying self‑administration, empowering adolescents 12 and older to treat at the earliest recognition of an attack."
The endorsement validates EKTERLY’s efficacy and safety profile, bolsters KalVista’s competitive advantage over established injectable therapies, and is expected to accelerate market adoption and drive sales growth. The guideline’s recommendation also signals strong confidence from the international HAE community, reinforcing KalVista’s positioning as a leader in oral HAE therapeutics.
The event is a material regulatory milestone that could reshape the competitive dynamics of the HAE treatment market and is likely to influence long‑term investment theses for stakeholders focused on rare disease therapeutics.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.